A prospective observational study of 468 patients undergoing D2 or D3 lymphadenectomy for gastric cancer

Hepatogastroenterology. 2013 May;60(123):624-7. doi: 10.5754/hge11507.

Abstract

Background/aims: A single-center, prospective observational study was performed to evaluate outcomes in patients undergoing D2 or D3 lymphadenectomy for gastric cancer.

Methodology: Lymphadenectomies were performed according to the classification published by the Japanese Gastric Cancer Association.

Results: Of 468 consecutive patients, 370 underwent D2 and 98 underwent D3 lymphadenectomy. Postoperative complications were significantly less common in the D2 group than in the D3 group (19.2% vs. 35.7%, p=0.001). Postoperative mortality in the two groups was similar, being 3.8% in the D2 group and 5.1% in the D3 group (p>0.05). Median postoperative survival times were also similar, in the D2 group being 37.8 months (95% CI: 23-52.5), and in the D3 group 30.2 months (95% CI: 13-47.3, p>0.05).

Conclusions: In patients who underwent gastrectomy with curative intent, lymphadenectomy that was more extensive than D2 did not provide a survival benefit compared to D2 dissection.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / secondary*
  • Adenocarcinoma / surgery*
  • Adult
  • Aged
  • Chi-Square Distribution
  • Female
  • Gastrectomy* / adverse effects
  • Gastrectomy* / mortality
  • Humans
  • Kaplan-Meier Estimate
  • Lymph Node Excision / adverse effects
  • Lymph Node Excision / methods*
  • Lymph Node Excision / mortality
  • Lymph Nodes / pathology*
  • Lymph Nodes / surgery*
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prospective Studies
  • Stomach Neoplasms / mortality
  • Stomach Neoplasms / pathology*
  • Stomach Neoplasms / surgery*
  • Time Factors
  • Treatment Outcome